Hepatitis C Virus: Insights Into Its History, Treatment, Challenges, and Future Directions

• Published in: Curēus (Palo Alto, CA) Vol. 15; no. 8; p. e43924
• Main Authors: Bernal, Luis A, Soti, Varun
• Format: Journal Article
• Language: English
• Published: United States Cureus Inc 22.08.2023; Cureus
• Subjects: Antigens; Antiviral drugs; Blood & organ donations; Blood transfusions; Chronic illnesses; Cloning; Collaboration; Disease; Epidemiology/Public Health; Food contamination & poisoning; Hepatitis A; Hepatitis B; Hepatitis C; Infections; Infectious Disease; Internal Medicine; Liver cirrhosis; Public health; Vaccines; Viral infections; Viruses; hepatitis c virus; hepatitis c virus (hcv); interferon alfa; ribavirin; direct-acting antivirals; pharmacoeconomic burden
• ISSN: 2168-8184; 2168-8184
• DOI: 10.7759/cureus.43924

Hepatitis C virus (HCV) is a global public health concern with significant impacts. It primarily spreads through blood-to-blood contact, such as sharing needles among drug users. Given the wide prevalence of risk factors, HCV continues to pose a major threat. Hence, it is crucial to understand its characteristics, structure, and genotypes to prevent, treat, and potentially eradicate it. This narrative review aims to explore the history of HCV treatment, highlight the breakthroughs achieved with direct-acting antiviral (DAA) therapy, address potential barriers to HCV eradication, and discuss future treatment possibilities. For this article, relevant studies were identified using various databases, including PubMed, ClinicalTrials.gov, and Journal Storage. The literature search revealed that after identifying HCV and studying its characteristics, interferon alfa and ribavirin became primary treatment options. However, due to their limited coverage against different HCV genotypes, ethnic variations, and suboptimal sustained virological response, the development of DAAs became essential. Combining various DAAs, such as sofosbuvir and velpatasvir, for a duration of 12 weeks has become the standard HCV treatment, with effectiveness against most genotypes. Additionally, ongoing clinical trials have shown promising results for other drugs such as CDI31244/sofosbuvir/velpatasvir, sofosbuvir/coblopasvir, and daclatasvir/asunaprevir. Despite the success of DAAs and ongoing efforts to discover more effective treatments, the high costs of DAAs pose a significant challenge to eradicating HCV, as not all patients can afford these expensive therapies. Furthermore, the ability of HCV to mutate limits the potential for vaccine development. Therefore, it is crucial to focus on developing more cost-effective strategies to control the spread of HCV and create novel, highly effective, and affordable DAAs.